The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Purpose Uveal melanoma (UM) leads to metastasis in up to 50% of the patients. Patients at risk are readily identified using an array of prognostic markers but an effective treatment is lacking. We recently identified Src as an important tyrosine kinase that conveys MAPK activation in UM. GNAQ/GNA11 mutations are the common denominators of oncogene signalling in UM and Src is a likely downstream kinase...
Purpose Intravitreal bevacizumab, a humanized monoclonal antibody to VEGF‐A, was originally developed as an anti‐tumour treatment, and is used to treat macular edema in radiation retinopathy. As this drug may potentially be used to treat primary uveal melanoma (UM) and/or its metastases, we analyzed the effect of bevacizumab on UM growth.
Methods Mice inoculated with B16F10 melanoma cells into the...